Logo image of INMD

INMODE LTD (INMD) Stock Fundamental Analysis

USA - NASDAQ:INMD - IL0011595993 - Common Stock

14.43 USD
-0.01 (-0.07%)
Last: 11/7/2025, 10:12:07 AM
Fundamental Rating

7

INMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making INMD a very profitable company, without any liquidiy or solvency issues. INMD is valued quite cheap, while showing a decent growth score. This is a good combination! This makes INMD very considerable for value investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

INMD had positive earnings in the past year.
INMD had a positive operating cash flow in the past year.
INMD had positive earnings in each of the past 5 years.
In the past 5 years INMD always reported a positive cash flow from operatings.
INMD Yearly Net Income VS EBIT VS OCF VS FCFINMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

The Return On Assets of INMD (25.23%) is better than 98.41% of its industry peers.
The Return On Equity of INMD (28.44%) is better than 97.88% of its industry peers.
Looking at the Return On Invested Capital, with a value of 16.27%, INMD belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for INMD is significantly above the industry average of 9.12%.
The 3 year average ROIC (22.89%) for INMD is well above the current ROIC(16.27%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 25.23%
ROE 28.44%
ROIC 16.27%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
INMD Yearly ROA, ROE, ROICINMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

INMD's Profit Margin of 44.50% is amongst the best of the industry. INMD outperforms 97.88% of its industry peers.
In the last couple of years the Profit Margin of INMD has grown nicely.
The Operating Margin of INMD (28.54%) is better than 95.24% of its industry peers.
In the last couple of years the Operating Margin of INMD has declined.
INMD has a better Gross Margin (79.98%) than 92.59% of its industry peers.
In the last couple of years the Gross Margin of INMD has declined.
Industry RankSector Rank
OM 28.54%
PM (TTM) 44.5%
GM 79.98%
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
INMD Yearly Profit, Operating, Gross MarginsINMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INMD is creating value.
INMD has less shares outstanding than it did 1 year ago.
The number of shares outstanding for INMD has been increased compared to 5 years ago.
INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INMD Yearly Shares OutstandingINMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
INMD Yearly Total Debt VS Total AssetsINMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.85
WACC8.79%
INMD Yearly LT Debt VS Equity VS FCFINMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

A Current Ratio of 9.60 indicates that INMD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 9.60, INMD belongs to the best of the industry, outperforming 92.59% of the companies in the same industry.
INMD has a Quick Ratio of 8.58. This indicates that INMD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INMD (8.58) is better than 92.06% of its industry peers.
Industry RankSector Rank
Current Ratio 9.6
Quick Ratio 8.58
INMD Yearly Current Assets VS Current LiabilitesINMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

4

3. Growth

3.1 Past

The earnings per share for INMD have decreased strongly by -23.67% in the last year.
Measured over the past years, INMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.97% on average per year.
The Revenue for INMD has decreased by -19.76% in the past year. This is quite bad
The Revenue has been growing by 20.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-23.67%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%-45.71%
Revenue 1Y (TTM)-19.76%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%-28.46%

3.2 Future

The Earnings Per Share is expected to grow by 1.66% on average over the next years.
Based on estimates for the next years, INMD will show a small growth in Revenue. The Revenue will grow by 0.63% on average per year.
EPS Next Y-9.5%
EPS Next 2Y-1.61%
EPS Next 3Y1.66%
EPS Next 5YN/A
Revenue Next Year-8.12%
Revenue Next 2Y-1.77%
Revenue Next 3Y0.63%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INMD Yearly Revenue VS EstimatesINMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
INMD Yearly EPS VS EstimatesINMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 9.13, the valuation of INMD can be described as very reasonable.
INMD's Price/Earnings ratio is rather cheap when compared to the industry. INMD is cheaper than 93.12% of the companies in the same industry.
INMD is valuated cheaply when we compare the Price/Earnings ratio to 25.67, which is the current average of the S&P500 Index.
INMD is valuated reasonably with a Price/Forward Earnings ratio of 8.37.
Based on the Price/Forward Earnings ratio, INMD is valued cheaper than 95.77% of the companies in the same industry.
INMD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 31.86.
Industry RankSector Rank
PE 9.13
Fwd PE 8.37
INMD Price Earnings VS Forward Price EarningsINMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

98.41% of the companies in the same industry are more expensive than INMD, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of INMD indicates a rather cheap valuation: INMD is cheaper than 97.35% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.77
EV/EBITDA 1.9
INMD Per share dataINMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The excellent profitability rating of INMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.4
EPS Next 2Y-1.61%
EPS Next 3Y1.66%

0

5. Dividend

5.1 Amount

No dividends for INMD!.
Industry RankSector Rank
Dividend Yield N/A

INMODE LTD

NASDAQ:INMD (11/7/2025, 10:12:07 AM)

14.43

-0.01 (-0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-02 2026-02-02/bmo
Inst Owners58.73%
Inst Owner Change-0.44%
Ins Owners10.65%
Ins Owner ChangeN/A
Market Cap912.12M
Revenue(TTM)394.82M
Net Income(TTM)178.70M
Analysts72.31
Price Target16.98 (17.67%)
Short Float %5.35%
Short Ratio3.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.54%
Min EPS beat(2)-13.69%
Max EPS beat(2)10.61%
EPS beat(4)2
Avg EPS beat(4)-3.62%
Min EPS beat(4)-20.27%
Max EPS beat(4)10.61%
EPS beat(8)3
Avg EPS beat(8)-6.64%
EPS beat(12)7
Avg EPS beat(12)-0.75%
EPS beat(16)11
Avg EPS beat(16)1.82%
Revenue beat(2)0
Avg Revenue beat(2)-2.62%
Min Revenue beat(2)-2.87%
Max Revenue beat(2)-2.38%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-9.96%
Max Revenue beat(4)0.53%
Revenue beat(8)1
Avg Revenue beat(8)-7%
Revenue beat(12)5
Avg Revenue beat(12)-3.84%
Revenue beat(16)9
Avg Revenue beat(16)-1.49%
PT rev (1m)2.46%
PT rev (3m)-2.35%
EPS NQ rev (1m)0.84%
EPS NQ rev (3m)5.98%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-6.83%
Revenue NQ rev (1m)1.22%
Revenue NQ rev (3m)0.94%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-3.27%
Valuation
Industry RankSector Rank
PE 9.13
Fwd PE 8.37
P/S 2.27
P/FCF 8.77
P/OCF 8.72
P/B 1.45
P/tB 1.45
EV/EBITDA 1.9
EPS(TTM)1.58
EY10.95%
EPS(NY)1.72
Fwd EY11.94%
FCF(TTM)1.65
FCFY11.4%
OCF(TTM)1.65
OCFY11.47%
SpS6.35
BVpS9.94
TBVpS9.94
PEG (NY)N/A
PEG (5Y)0.4
Graham Number18.8
Profitability
Industry RankSector Rank
ROA 25.23%
ROE 28.44%
ROCE 17.86%
ROIC 16.27%
ROICexc 79.63%
ROICexgc 79.63%
OM 28.54%
PM (TTM) 44.5%
GM 79.98%
FCFM 25.9%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
ROICexc(3y)532.49%
ROICexc(5y)5023.19%
ROICexgc(3y)532.49%
ROICexgc(5y)5023.19%
ROCE(3y)25.13%
ROCE(5y)28.51%
ROICexgc growth 3Y-60.68%
ROICexgc growth 5YN/A
ROICexc growth 3Y-60.68%
ROICexc growth 5YN/A
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 81.89%
Cap/Sales 0.15%
Interest Coverage 250
Cash Conversion 90.67%
Profit Quality 58.19%
Current Ratio 9.6
Quick Ratio 8.58
Altman-Z N/A
F-Score7
WACC8.79%
ROIC/WACC1.85
Cap/Depr(3y)144.54%
Cap/Depr(5y)147.73%
Cap/Sales(3y)0.22%
Cap/Sales(5y)0.23%
Profit Quality(3y)91.09%
Profit Quality(5y)96.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-23.67%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%-45.71%
EPS Next Y-9.5%
EPS Next 2Y-1.61%
EPS Next 3Y1.66%
EPS Next 5YN/A
Revenue 1Y (TTM)-19.76%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%-28.46%
Revenue Next Year-8.12%
Revenue Next 2Y-1.77%
Revenue Next 3Y0.63%
Revenue Next 5YN/A
EBIT growth 1Y-14.49%
EBIT growth 3Y-12.42%
EBIT growth 5Y13.55%
EBIT Next Year-39.83%
EBIT Next 3Y-11.3%
EBIT Next 5YN/A
FCF growth 1Y-40.81%
FCF growth 3Y-8.8%
FCF growth 5Y16.5%
OCF growth 1Y-40.87%
OCF growth 3Y-8.8%
OCF growth 5Y16.36%

INMODE LTD / INMD FAQ

Can you provide the ChartMill fundamental rating for INMODE LTD?

ChartMill assigns a fundamental rating of 7 / 10 to INMD.


What is the valuation status for INMD stock?

ChartMill assigns a valuation rating of 8 / 10 to INMODE LTD (INMD). This can be considered as Undervalued.


How profitable is INMODE LTD (INMD) stock?

INMODE LTD (INMD) has a profitability rating of 9 / 10.


What are the PE and PB ratios of INMODE LTD (INMD) stock?

The Price/Earnings (PE) ratio for INMODE LTD (INMD) is 9.13 and the Price/Book (PB) ratio is 1.45.


What is the financial health of INMODE LTD (INMD) stock?

The financial health rating of INMODE LTD (INMD) is 8 / 10.